Noxopharm Ltd (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.
The company has three active drug development programs: its clinical drug candidate Veyonda®, plus two innovative technology platforms – ChromaTM (oncology) and SofraTM (mRNA vaccines, inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.